ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 639.5 DKK | +3.56% |
|
+9.04% | +71.36% |
| Sales 2024 * | 441M 64.11M | Sales 2025 * | 1.02B 148M | Capitalization | 39.84B 5.79B |
|---|---|---|---|---|---|
| Net income 2024 * | -653M -94.97M | Net income 2025 * | -399M -58.03M | EV / Sales 2024 * | 85 x |
| Net cash position 2024 * | 2.37B 345M | Net cash position 2025 * | 2.44B 355M | EV / Sales 2025 * | 36.7 x |
| P/E ratio 2024 * |
-64
x | P/E ratio 2025 * |
-67.3
x | Employees | 270 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| 1 day | +3.56% | ||
| 1 week | +9.04% | ||
| 1 month | +1.03% | ||
| 3 months | -3.69% | ||
| 6 months | +90.33% | ||
| Current year | +71.36% |
1 week
583.50
641.00
1 month
560.00675.00
Current year
342.20749.00
1 year
212.20749.00
3 years
69.55749.00
5 years
69.55749.00
10 years
58.00749.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 09-12-31 | |
| Director of Finance/CFO | - | 22-10-31 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-04-03 |
| Chairman | 69 | 14-12-31 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18-04-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 45 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 639.5 | +3.56% | 396,087 |
| 24-05-30 | 617.5 | +0.41% | 180,884 |
| 24-05-29 | 615 | +0.08% | 176,249 |
| 24-05-28 | 614.5 | -0.41% | 237,079 |
| 24-05-27 | 617 | +5.20% | 303,643 |
Delayed Quote Nasdaq Copenhagen, May 31, 2024 at 10:59 am EDT
More quotes
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
639.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+22.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +71.36% | 5.79B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ZEAL Stock
